$35.8 Million is the total value of KPCB XV Associates, LLC's 3 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RAPT | Sell | Rapt Therapeutics, Inc. | $15,604,000 | -34.1% | 648,531 | -50.0% | 43.54% | -0.3% |
| TWLO | Twilio Inc. | $13,140,000 | -17.5% | 190,047 | 0.0% | 36.66% | +24.8% | |
| ATRA | Atara Biotherapeutics, Inc. | $7,094,000 | -51.5% | 1,876,650 | 0.0% | 19.80% | -26.6% | |
| AUGX | Exit | Augmedix, Inc. | $0 | – | -708 | -100.0% | -0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-10-26
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Twilio Inc. | 8 | Q3 2022 | 54.3% |
| Rapt Therapeutics, Inc. | 8 | Q3 2022 | 43.7% |
| Atara Biotherapeutics, Inc. | 8 | Q3 2022 | 27.0% |
| Upstart Holdings, Inc. | 3 | Q2 2021 | 42.4% |
| Augmedix, Inc. | 2 | Q2 2022 | 0.0% |
View KPCB XV Associates, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-10-26 |
| 13F-HR | 2022-07-21 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-10-25 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-13 |
| 13F-HR | 2021-02-16 |
| 4 | 2020-10-20 |
| 4 | 2020-09-11 |
View KPCB XV Associates, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.